Melatonin as a Neuroprotective Agent in the Rodent Models of Parkinson’s Disease: Is it All Set to Irrefutable Clinical Translation?

2011 ◽  
Vol 45 (1) ◽  
pp. 186-199 ◽  
Author(s):  
Naveen Kumar Singhal ◽  
Garima Srivastava ◽  
Sonal Agrawal ◽  
Swatantra Kumar Jain ◽  
Mahendra Pratap Singh
Author(s):  
Mohammad Zamanian ◽  
Małgorzata Kujawska ◽  
Marjan Nikbakht Zadeh ◽  
Amin Hassanshahi ◽  
Soudeh Ramezanpour ◽  
...  

Background & objective: Neurological diseases are becoming a significant problem worldwide, with the elderly at a higher risk of being affected. Several researchers have investigated the neuroprotective effects of Carvacrol (CAR) (5-isopropyl-2-methyl phenol). This review systematically surveys the existing literature on the impact of CAR when used as a neuroprotective agent in neurological diseases. Methods: The systematic review involved English articles published in the last ten years obtained from PubMed, Google Scholar, and Scopus databases. The following descriptors were used to search the literature: “Carvacrol” [Title] AND “neuroprotective (neuroprotection)” [Title] OR “stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, seizure, epilepsy [Title]. Results: : A total of 208 articles were retrieved during the search process, but only 20 studies met the eligibility criteria and were included for review. A total of 20 articles were identified, in which the efficacy of CAR was described in experimental models of stroke, traumatic brain injury, Parkinson’s disease, Alzheimer’s disease, , epilepsy, and seizure, through motor deficits improvements in neurochemical activity, especially antioxidant systems, reducing inflammation, oxidative stress and apoptosis as well as inhibition of TRPC1 and TRPM7. Conclusion : The data presented in this study support the beneficial impact of CAR on behavioural and neurochemical deficits. CAR benefits accrue because of its anti-apoptotic, antioxidant, and anti-inflammatory properties. Therefore, CAR has emerged as an alternative treatment for neurological disorders based on its properties.


2006 ◽  
Vol 11 (1) ◽  
pp. 77-96 ◽  
Author(s):  
Michael J. O'Neill ◽  
Tracey K. Murray ◽  
Michael P. Clay ◽  
Terry Lindstrom ◽  
Charles R. Yang ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Cheng-Fu Su ◽  
Li Jiang ◽  
Xiao-Wen Zhang ◽  
Ashok Iyaswamy ◽  
Min Li

Parkinson’s disease (PD) is a common neurodegenerative disease featured by progressive degeneration of nigrostriatal dopaminergic neurons (DA) accompanied with motor function impairment. Accumulating evidence has demonstrated that natural compounds from herbs have potent anti-PD efficacy in PD models. Among those compounds, resveratrol, a polyphenol found in many common plants and fruits, is more effective against PD. Resveratrol has displayed a potent neuroprotective efficacy in several PD animal models. However, there is still no systematic analysis of the quality of methodological design of these studies, nor of their results. In this review, we retrieved and analyzed 18 studies describing the therapeutic effect of resveratrol on PD animal models. There are 5 main kinds of PD rodent models involved in the 18 articles, including chemical-induced (MPTP, rotenone, 6-OHDA, paraquat, and maneb) and transgenic PD models. The neuroprotective mechanisms of resveratrol were mainly concentrated on the antioxidation, anti-inflammation, ameliorating mitochondrial dysfunction, and motor function. We discussed the disadvantages of different PD animal models, and we used meta-analysis approach to evaluate the results of the selected studies and used SYRCLE’s risk of bias tool to evaluate the methodological quality. Our analytical approach minimized the bias of different studies. We have also summarized the pharmacological mechanisms of resveratrol on PD models as reported by the researchers. The results of this study support the notion that resveratrol has significant neuroprotective effects on different PD models quantified using qualitative and quantitative methods. The collective information in our review can guide researchers to further plan their future experiments without any hassle regarding preclinical and clinical studies. In addition, this collective assessment of animal studies can provide a qualitative analysis of different PD animal models, either to guide further testing of these models or to avoid unnecessary duplication in their future research.


Author(s):  
Alessandro Stefani ◽  
Rocco Cerroni ◽  
Mariangela Pierantozzi ◽  
Vincenza D’Angelo ◽  
Laura Grandi ◽  
...  

2020 ◽  
Vol 11 ◽  
Author(s):  
Carolina Sportelli ◽  
Daniele Urso ◽  
Peter Jenner ◽  
K. Ray Chaudhuri

2018 ◽  
Vol 46 ◽  
pp. S10-S14 ◽  
Author(s):  
Paola Imbriani ◽  
Giuseppe Sciamanna ◽  
Massimo Santoro ◽  
Tommaso Schirinzi ◽  
Antonio Pisani

Sign in / Sign up

Export Citation Format

Share Document